BICX — Biocorrx Income Statement
0.000.00%
- $4.61m
- $6.92m
- $0.01m
Annual income statement for Biocorrx, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.123 | 0.048 | 0.214 | 0.089 | 0.008 |
Cost of Revenue | |||||
Gross Profit | 0.027 | 0.042 | 0.199 | 0.053 | 0.006 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 7.61 | 5.53 | 5.11 | 3.91 | 5.29 |
Operating Profit | -7.49 | -5.48 | -4.9 | -3.82 | -5.29 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -3.51 | -5.21 | -4.38 | -3.77 | -5.21 |
Provision for Income Taxes | |||||
Net Income After Taxes | -3.51 | -5.21 | -4.38 | -3.77 | -5.21 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -3.47 | -5.21 | -4.37 | -3.77 | -5.11 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.47 | -5.28 | -4.37 | -3.77 | -5.11 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.646 | -0.796 | -0.579 | -0.442 | -0.472 |